Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25105738 | 0.89 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL29597309 | 0.87 | KDM4E (0.51) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL29794433 | 0.85 | KDM4E (0.49) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL31391357 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL16431488 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL1010778 | 0.78 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL28843889 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL4250021 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL1571660 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA | |
| SCHEMBL27960877 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KDM4EPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2476679-B1 | Substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | ALDH1A1 4309/4885SMN1; SMN2 3354/4885KDM4E 4019/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | ALDH1A1 4309/4885SMN1; SMN2 3354/4885KDM4E 4019/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885KDM4E 177/4885 |
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885KDM4E 177/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885SMN1; SMN2 4701/4885KDM4E 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.